Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 8 to 17

Smart AFO and 5-Azacitidine to Improve Mobility in Children with Cerebral Palsy

Official title: Smart Ankle-Foot Orthosis and 5-Azacitidine to Enhance Gait and Community Mobility for Children With Cerebral Palsy

Run by Shirley Ryan AbilityLab · NCT07434492 · Data updated 2026-11-12

A 2nd-phase trial tests a smart ankle-foot brace, with some participants also receiving a mayo-like drug, to see if mobility improves for children with cerebral palsy.

More Cerebral Palsy trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages8 Years to 17 Years
SexAll
Enrollment60 (estimated)
SponsorShirley Ryan AbilityLab
Academic / other
Locations1 site (Chicago, Illinois)
StatusRecruiting
StartedMay 28, 2026
Main results expectedAugust 31, 2030
Study endsAugust 31, 2030
Registry record updatedJune 1, 2026
Trial IDNCT07434492 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Children aged 8 to 17 years 8 months with CP, GMFCS I–III, who can walk for at least 6 minutes and meet safety and device-fit criteria.

Probably not a fit

Children who cannot tolerate the device, have unstable medical conditions, or do not meet the gait or range-of-motion requirements may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 interventional study evaluates the Biomotum Ambulo smart ankle-foot orthosis (AFO) for improving gait and mobility in children with cerebral palsy (GMFCS I–III). Participants undergo a 6-week at-home training program with the smart AFO and may opt into a 1:1 randomization to receive 5-azacitidine or placebo to explore potential additive effects on muscle function. The study also collects blood samples to examine genetic and epigenetic factors related to musculoskeletal outcomes and responses to the interventions. Primary aims include improvements in walking ability and ankle mechanics, driven by both mechanical support and progressive resistance-based exercise. The trial is conducted at Shirley Ryan AbilityLab in Chicago, with appropriate caregiver involvement and safety monitoring.

Why it matters

Potential benefit: If successful, the approach could enhance mobility and quality of life for children with CP by combining orthotic support with targeted muscle benefits.

How similar studies have gone: Previous work suggests orthotic devices can aid gait, but combining a smart AFO with 5-azacitidine is a novel approach in pediatric CP and warrants exploration.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Diagnosis of cerebral palsy classified as Gross Motor Function Classification System (GMFCS) levels I to III
* Between 8 and 17 years and 8 months of age at the time of enrollment/consent. Participants that will turn 18 during the course of the study will not be included as pausing the at-home protocol until re-consenting is possible could interfere with intervention results.
* Stable medical condition as determined by the investigator.
* Adequate caregiver support to be able to participate in training and assessment sessions for the duration of the study, at the discretion of the PI.
* Height/weight/BMI between the 5th - 95th percentile of children with cerebral palsy
* Able to walk for at least 6 minutes (assisted or unassisted)
* Able to understand and follow simple directions
* Able to safely fit into a device configuration and tolerate assistance without knee hyperextension while walking
* At least 20 degrees of passive ankle plantar flexion range of motion
* Physician approval for participation

Exclusion Criteria:

* Knee extension or ankle dorsiflexion contractures greater than 15 degrees
* Immunodeficiency or hematologic condition
* Allergy to AZA or mannitol
* Plans to receive a vaccine within 30 days of the planned AZA or placebo injection to take place at week 5
* Pregnancy
* Orthopedic surgery on the lower limbs completed in the prior 12 months
* New implanted device (e.g., baclofen pump) and/or active intrathecal medication titration that may affect muscle spasticity
* Botulinum toxin treatment within 3 months preceding enrollment unless given approval by the study physician
* Severe osteoporosis unless given approval by the study physician
* Current enrollment in a conflicting research study
* Any other health condition or diagnosis not listed above that may put the participant at risk as determined by the PI or study physician

Where it's running

  • Shirley Ryan AbilityLab
    Chicago, Illinois, United States
    Recruiting

Study contacts

  • Principal investigator: Megan O'Brien, PhD — Shirley Ryan AbilityLab
  • Study coordinator: Audrey Wiesner, BS
  • Email: awiesner@sralab.org
  • Phone: 3122388435

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.